Instructions for Nurofen Express Forte (Ibuprofen)
English product name
Nurofen® Express Forte
Release form
Capsules
Description:
The capsules are oval, with a translucent gelatine shell in red, with an identifying inscription in white "Nurofen"; The contents of the capsules are clear liquid from colorless to light pink.
1 cap.
Ibuprofen 400 mg
Auxiliary substances: macrogol 600 - 335.3 mg, potassium hydroxide - 44.82 mg, water - 29.88 mg.
Shell Composition:
gelatin - 197 mg,
sorbitol (partially dehydrated) - 95.68 mg, water - 25.02 mg, powder dye [Ponso 4R] (E124) - 0.79 mg, white ink [Opacod WB NS-78-18011] (water 48%, titanium dioxide (E171) 29%, propylene glycol 10%, isopropanol 8%, hypromellose 3cP 5%).
ATC codes
M01AE01 Ibuprofen
Clinical-pharmacological groups / Group affiliation
NAPS
Active substance
Ibuprofen
Pharmacotherapy group
NSAIDs
Testimony Nurofen:
- Symptomatic treatment as anti-inflammatory and antipyretic:
- inflammatory and degenerative diseases of joints and spine (including rheumatic and rheumatoid arthritis, ankylosing spondylitis, osteoarthrosis),
- joint syndrome in acute gout,
- psoriatic arthritis,
- ankylosing spondylitis,
- tendinitis,
- bursitis,
- radiculitis,
- traumatic inflammation of the soft tissues and musculoskeletal system.
- Neuralgia,
- myalgia,
- pain syndrome in infectious and inflammatory diseases of ENT organs, adnexitis, algodismenorrhea, headache and toothache. Fever in infectious and inflammatory diseases, in childhood infections, in post-vaccination reactions in children (in appropriate dosage forms).
How to take the drug Nurofen:
Set individually, depending on the indications, the severity of clinical manifestations, the age of the patient.
Application for kidney disorders
It is contraindicated in pronounced kidney dysfunction. It is used with caution in the associated diseases of the kidneys.
Use in liver disorders
It is contraindicated in cases of pronounced liver dysfunctions. It is used with caution in the case of associated liver diseases.
Application in elderly patients
Care should be taken to prescribe elderly patients in order to avoid the deterioration of underlying health conditions.
In older patients, there is an increased frequency of adverse reactions associated with NSAIDs, especially gastrointestinal bleeding and perforations, in some cases fatal.
Use in children
Ibuprofen is contraindicated for rectal use in children with a child body weight of up to 6 kg; For oral use - in children under 6 years of age (200 mg dose), in children under 12 years of age (400 mg dose).
Nosology Nurofen (ICD codes)
H92.0
Otalgia
K08.8
Other refined changes of teeth and their support apparatus (including toothache)
M05
Seropositive rheumatoid arthritis
M07
Psoriatic and enteropathic arthropathy
M10
Podagra
M15
Polyarthrosis
M19.9
Arthrosis unspecified
M25.5
Joint pain
M42
Spinal osteochondrosis
M45
Ankylosing spondylitis
M47
Spondylosis
M54
Dorsalgia
M54.1
Radikulopathy
M54.3
Ishias
M54.4
Lumbago with Sciatica
M65
Synovitis and tenosinovites
M70
Soft tissue diseases related to load, overload and pressure
M71
Other bursopathy
M79.1
Mialgia
M79.2
Neuralgia and Neuritis Unspecified
N70
Salpingitis and oophorite
N94.4
Primary dysmenorrhea
N94.5
Secondary dysmenorrhea
R07.0
Sore throat
R50
Fever of uncertain origin
R51
Headache
R52.0
Acute pain
R52.2
Other persistent pain (chronic)
T14.3
Dislocation, stretching and overtension of the capsule-bonding apparatus of the unspecified body region joint
Pharmacological effect Nurofen:
NSAIDs, a phenylpropionic acid derivative. It has anti-inflammatory, analgesic and antipyretic effects.
The mechanism of action is associated with the suppression of the activity of COX, the main enzyme of peanut acid metabolism, a precursor to prostaglandins, which play a major role in the pathogenesis of inflammation, pain and fever. Analgesic effect is caused by both peripheral (indirectly, through the suppression of prostaglandin synthesis) and central mechanism (by inhibition of prostaglandin synthesis in the central and peripheral nervous system). Suppresses platelet aggregation
